| Name | Title | Contact Details |
|---|
Strategyx is a Somerville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SCOLR Pharma Inc is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Havas Health & You is a unique health and wellness network focused on promoting healthy living decisions across the entire health ecosystem. We believe in putting YOU – our employees, business partners, and our customers – at the center of everything we do. By understanding what you need and crafting unique solutions, we can help you stay and live well.
Medican Enterprises is a bio-pharmaceutical company focused on developing, distributing and marketing pharmaceutical grade cannabis to the emerging global medical marijuana market. It’s wholly owned subsidiary Medican Systems Inc. is an industry leader in the design, construction and operation of Medical Marijuana and Cultivation Centers across Canada and the United States. Traded on the OTCBB, Medican drives shareholder value through its scalable business model and commitment to scientific research, operational excellence and regulatory compliance.
Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius` RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.